Foundayo (orforglipron) met its heart-safety goal in the phase 3 ACHIEVE-4 trial. In 2,749 high-risk adults with type 2 diabetes, major heart events occurred in 4.2% of participants on orforglipron and 5.0% on insulin glargine over a median follow-up of 2 years. The result met the trial's preset noninferiority standard. It did not show that orforglipron reduces heart events.
The results were published in The Lancet on September 30, 2026, and presented the same day at the European Association for the Study of Diabetes (EASD) annual meeting in Milan. ACHIEVE-4 is the first trial to assess the cardiovascular safety of a non-peptide, small-molecule GLP-1 receptor agonist.
Key Points
- Trial: ACHIEVE-4, a phase 3, event-driven, randomized, open-label, noninferiority trial comparing once-daily oral orforglipron with titrated insulin glargine.
- Participants: 2,749 adults with type 2 diabetes and overweight or obesity at increased cardiovascular risk, enrolled at 317 sites in 16 countries.
- Primary outcome: Four-component MACE occurred in 4.2% on orforglipron vs 5.0% on insulin glargine (HR 0.84; 95% CI 0.59–1.20), meeting noninferiority.
- Superiority: Not shown. Three-component MACE had a hazard ratio of 0.77 (95% CI 0.52–1.13; p = 0.18).
- Blood sugar and weight: At week 52, HbA1c fell an additional 0.50 percentage points and body weight an additional 8.9% on orforglipron vs insulin glargine, with differences sustained through 104 weeks.
- Safety: Gastrointestinal events were more common on orforglipron (62.1% vs 14.2%). Severe hypoglycemia was less common on orforglipron (6.8% vs 19.2%).
What MACE Means
MACE stands for major adverse cardiovascular events. In ACHIEVE-4, the primary outcome was four-component MACE, or MACE-4: cardiovascular death, non-fatal heart attack, non-fatal stroke, or hospitalization for unstable angina. The trial also tracked three-component MACE, or MACE-3, which leaves out hospitalization for unstable angina.
What Noninferiority Means
A noninferiority trial tests whether a new treatment is not worse than an existing treatment by more than a preset amount. In ACHIEVE-4, orforglipron was declared noninferior to insulin glargine if the upper limit of the 95% confidence interval for the hazard ratio stayed below 1.8. The observed upper limit was 1.20, so the trial met its standard.
Noninferiority is a safety finding, not a benefit finding. ACHIEVE-4 was designed to show that orforglipron does not increase cardiovascular risk compared with insulin glargine. It was not designed to show that orforglipron lowers the risk of heart events.
The Results in Detail
Between May 2023 and September 2024, investigators randomly assigned 1,371 participants to orforglipron and 1,378 to insulin glargine. Over a median follow-up of 2 years, the primary outcome occurred in 57 of 1,358 orforglipron participants (4.2%) and 67 of 1,343 insulin glargine participants (5.0%). The hazard ratio was 0.84 (95% CI 0.59–1.20; p < 0.0001 for noninferiority).
For three-component MACE, the hazard ratio was 0.77 (95% CI 0.52–1.13; p = 0.18). Because that result did not reach statistical significance, the trial does not support a claim that orforglipron reduces heart events.
Deaths occurred in 19 participants on orforglipron (1.4%) and 43 on insulin glargine (3.2%). Pre-planned analyses put the hazard ratio for all-cause death at 0.43 and for cardiovascular death at 0.47. Those analyses were not controlled for multiplicity, so the mortality differences are exploratory and cannot be treated as proof of a survival benefit.
The weekly GLP-1 email
Plain-English answers on side effects, eating, cost and the newest medications. Free, one email a week.
Blood Sugar, Weight, and Side Effects
At week 52, orforglipron reduced HbA1c by an additional 0.50 percentage points and body weight by an additional 8.9% compared with insulin glargine, and those differences were sustained through 104 weeks. Insulin glargine tends to cause weight gain, so part of the weight difference reflects the comparator rather than orforglipron alone.
Gastrointestinal adverse events were reported in 62.1% of orforglipron participants and 14.2% of insulin glargine participants. Gastrointestinal events were the most frequent adverse event and the most common reason for stopping treatment. About 1 in 10 participants on orforglipron stopped treatment because of adverse events.
Clinically significant or severe hypoglycemia (glucose below 54 mg/dL) occurred in 6.8% of orforglipron participants and 19.2% of insulin glargine participants. Lower hypoglycemia risk is an expected difference between a GLP-1 receptor agonist and insulin, which directly lowers blood glucose.
What the Study Does Not Show
ACHIEVE-4 does not show that Foundayo protects the heart. The trial compared orforglipron with insulin glargine, not with placebo, so it cannot measure whether orforglipron lowers heart-event risk in absolute terms. It also cannot show how orforglipron compares with other GLP-1 medications on heart outcomes, since no other GLP-1 was a comparator.
Three limits matter when reading the results. The trial was open-label, so participants and investigators knew which treatment each person received. The noninferiority margin of 1.8 was wide, which makes the noninferiority standard easier to meet. And the participants were adults with type 2 diabetes at increased cardiovascular risk, so the findings do not extend directly to people taking Foundayo for weight management without diabetes or elevated heart risk.
The trial was funded by Eli Lilly, the maker of Foundayo. Foundayo (orforglipron) was approved in the US for chronic weight management in April 2026.
Bottom Line
ACHIEVE-4 confirmed the cardiovascular safety of Foundayo (orforglipron) against insulin glargine in high-risk adults with type 2 diabetes: major heart events occurred in 4.2% vs 5.0% over a median of 2 years, meeting noninferiority without showing superiority. The trial also showed greater HbA1c and weight reductions and less severe hypoglycemia than insulin glargine, with more gastrointestinal side effects. It does not show that orforglipron reduces heart events.
This article summarizes published trial results for information only. It is not medical advice. Talk to your prescriber about whether any GLP-1 medication fits your health history and treatment goals.
Sources
- Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. The Lancet. Published September 30, 2026. DOI: 10.1016/S0140-6736(26)01865-9. PubMed record
- Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4 — Pharmacy Times, October 5, 2026



